News Sentiment

XBIT sentiment intelligence

XBiotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.29 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.4% over one week, -2.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading Continues - IPO Entry Watch

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend inactive -2.1% over four weeks
Fair value -47.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 33
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
TradingKey 8
Market source 6
dars.gov.et 3
Ad Hoc News 2
Stock Titan 2
simplywall.st 2
The Manila Times 1

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 14
Regulatory and legal 4
Balance sheet 2
Capital return 2
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
Ad Hoc News Direct company coverage

XBiotech focuses on antibody pipeline as biotech sector evolves

XBiotech Inc. is advancing its antibody-based therapies in the competitive biotech sector, concentrating on specific inflammatory and oncology indications to optimize capital and address significant patient needs. The company's strategy involves developing human-derived antibodie

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 17:48
Source
Ad Hoc News
TradingView Direct company coverage

ETFs Investing in XBiotech, Inc. Stocks

This article lists ETFs that invest in XBiotech, Inc. stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each ETF. It highlights two specific ETFs: Bridgeway Omni Small-Cap Value ETF (BSVO) and Avantis U.S. Small Cap Value ETF

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 11:40
Source
TradingView
TradingView Direct company coverage

XBiotech, Inc. Actuals & Estimates (SWB:4XB)

The article provides an overview of XBiotech, Inc.'s financial actuals and estimates, including income statement, balance sheet, and cash flow data, available on TradingView. It also addresses frequently asked questions about the company's stock ticker (4XB on SWB), historical st

Tone
Neutral 50/100
Event
Balance sheet
Published
28 Jun 2026 20:09
Source
TradingView
TradingView Direct company coverage

XBiotech, Inc. Actuals & Estimates (MUN:4XB)

This article provides an overview of XBiotech, Inc. (MUN:4XB) financial data and analyst estimates available on TradingView. It includes information on the company's income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with e

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of XBiotech Inc. – NASDAQ:XBIT

This page provides access to the "Price to book forward" financial metric for XBiotech Inc. (NASDAQ:XBIT) on TradingView. It specifies the data period, value, and change, noting that the content is made by humans and supported by various financial data providers. The main focus i

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:09
Source
TradingView
TradingView Direct company coverage

XBiotech, Inc. Actuals & Estimates (FWB:4XB)

This TradingView page provides actuals and estimates for XBiotech, Inc. (FWB:4XB), allowing users to explore reported financial data and analyst estimates across various financial statements. It includes information on the company's stock ticker, all-time high and low prices, net

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 03:40
Source
TradingView
TradingView Direct company coverage

XBiotech, Inc. Actuals & Estimates (LS:A14QF1)

This article provides financial actuals and estimates for XBiotech, Inc. (A14QF1) on TradingView, detailing its current stock price, market capitalization, and historical performance. It also includes frequently asked questions about the company's stock, financials, and how to in

Tone
Negative 38/100
Event
Market update
Published
26 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT)

This article provides an overview of XBiotech Inc. (NASDAQ:XBIT) financial actuals and estimates, including its current stock price, historical performance, market capitalization, and volatility. It also touches upon frequently asked questions regarding its stock ticker, net inco

Tone
Negative 39/100
Event
Market update
Published
26 Jun 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of XBiotech Inc. – NASDAQ:XBIT

This article provides financial information for XBiotech Inc. (NASDAQ: XBIT), specifically focusing on its price-to-sales forward metric. The content highlights that XBiotech is a health technology and biotechnology company listed on the Nasdaq Stock Market, and it presents an ov

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

XBiotech, Inc. Actuals & Estimates (BOATS:XBIT)

This article provides an overview of XBiotech Inc.'s financial actuals and estimates available on TradingView, covering income statements, balance sheets, and cash flow. It also includes frequently asked questions about the company's stock ticker, historical prices, net income, a

Tone
Neutral 50/100
Event
Balance sheet
Published
25 Jun 2026 21:11
Source
TradingView
TradingKey Direct company coverage

XBiotech Inc (XBIT) Institutional Confidence

The article provides an overview of XBiotech Inc.'s (XBIT) institutional confidence score and shareholding details. XBIT has a current institutional shareholding score of 3.00, ranking 193rd in its industry, with a 12.25% institutional shareholding proportion showing a 42.58% qua

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 14:39
Source
TradingKey
TradingKey Direct company coverage

XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of XBiotech Inc's (XBIT) financial health, noting its strong financial status and high operating efficiency with a current financial score of 6.88. The analysis covers profitability and balance sheet aspects, though specific financial data for se

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:10
Source
TradingKey
TradingKey Direct company coverage

XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for XBiotech Inc (XBIT), highlighting that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company for FY2023. It shows current stock performance information for XBI

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for XBiotech Inc (XBIT) from TradingKey. It notes that no earnings forecast score is currently available for XBiotech Inc., contrasting with the Biotechnology & Medical Research industry's average score of 8.15. The report also indicates

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 03:39
Source
TradingKey
TradingKey Direct company coverage

XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for XBiotech Inc (XBIT), highlighting its current valuation score and P/E ratio within the Biotechnology & Medical Research industry. It notes that key P/B, P/S, and P/CF data have not been disclosed by the company. The analysis also inc

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of XBiotech Inc (XBIT), focusing on its price momentum, support and resistance levels, and key technical indicators. It notes that XBIT's current price momentum score is 5.68, ranking 310 out of 388 in its industry, and the stock is trad

Tone
Negative 38/100
Event
Market update
Published
17 Jun 2026 21:09
Source
TradingKey
TradingKey Direct company coverage

XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of XBiotech Inc (XBIT), listing both major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities. Key shareholde

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 15:09
Source
TradingKey
The Manila Times Direct company coverage

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

XBiotech Inc. has announced the launch of a Phase II clinical trial (V-SPINE) for vilamakitug, a potential treatment for active axial spondyloarthritis, after its Investigational New Drug application cleared the FDA's 30-day review. This study will evaluate the efficacy and safet

Tone
Positive 95/100
Event
Regulatory and legal
Published
17 Jun 2026 10:40
Source
The Manila Times
TradingKey Direct company coverage

XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of XBiotech Inc's (XBIT) dividend and stock split history. It notes that no dividends have been distributed over the past five years and no stock splits have been recorded. The page displays the current stock price, market cap, and links to other

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 06:09
Source
TradingKey
Intellectia AI Direct company coverage

XBiotech Receives Authorization for V-SPINE Trial

XBiotech has received FDA authorization to begin its V-SPINE trial, which will enroll 150 patients with active axial spondyloarthritis to evaluate the efficacy of Vilamakitug (XP2001 or Natrunix). This IgG4 monoclonal antibody targets IL-1α, aiming to reduce structural damage and

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 05:39
Source
Intellectia AI
AD HOC NEWS Direct company coverage

XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondyloarthritis

The FDA has cleared XBiotech Inc. to proceed with its Phase II V-SPINE trial of vilamakitug for active axial spondyloarthritis, marking a restart of the company's rheumatology program. This regulatory approval allows XBiotech to begin enrolling patients in the U.S. for the random

Tone
Positive 70/100
Event
Regulatory and legal
Published
16 Jun 2026 01:09
Source
AD HOC NEWS
Investing.com Direct company coverage

XBiotech clears FDA review for axial spondyloarthritis study

XBiotech Inc. has announced that its Investigational New Drug application for the V-SPINE study successfully completed the FDA's 30-day review period without a clinical hold, allowing the company to proceed with patient enrollment in the U.S. for its Phase II axial spondyloarthri

Tone
Positive 75/100
Event
Regulatory and legal
Published
15 Jun 2026 13:09
Source
Investing.com
Stock Titan Direct company coverage

FDA review lets XBiotech resume rheumatology with axial spondyloarthritis trial

XBiotech (NASDAQ: XBIT) announced FDA clearance for its Phase II V-SPINE trial of vilamakitug for active axial spondyloarthritis, allowing U.S. patient enrollment. The IND application completed its 30-day review without clinical hold, marking the resumption of XBiotech’s rheumato

Tone
Positive 71/100
Event
Market update
Published
15 Jun 2026 13:09
Source
Stock Titan
Finviz Direct company coverage

XBIT - XBiotech Inc Dividends

This article provides a detailed financial overview of XBiotech Inc (XBIT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists dividend information such as the ex-dividend date (July 15, 2021) and performance metrics

Tone
Neutral 50/100
Event
Capital return
Published
03 Jun 2026 20:41
Source
Finviz
Ad Hoc News Direct company coverage

XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update

XBiotech Inc. (XBIT) shares traded sideways on Nasdaq on June 2, 2026, as the Austin-based biotech company awaits its next earnings update. With no new company filings or press releases on the day, investor expectations are still shaped by results reported in late 2024. The compa

Tone
Neutral 50/100
Event
Earnings
Published
02 Jun 2026 13:39
Source
Ad Hoc News